Silence Therapeutics, a global clinical-stage biotechnology company developing novel short interfering RNA (siRNA) therapies, has priced its previously announced underwritten public offering of 12,962,963 ADS, each representing three ordinary shares…
UK: Silence prices upsized US$175m ADS offering
…
…






